Trial Details
RECRUITINGBasic Information
| Clinical ID | c91 |
|---|---|
| Identifier | NCT07186101 |
| Trial Title | LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: LY4268989|DRUG: Mirikizumab|DRUG: LY4268989 Placebo |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Scottsdale |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-11-11 |
|---|---|
| Primary Completion Date | 2027-05 |
| Completion Date | 2029-03 |